Research programme: adipose-derived stem cell therapeutics - American CryoStem Corporation/Rutgers

Drug Profile

Research programme: adipose-derived stem cell therapeutics - American CryoStem Corporation/Rutgers

Alternative Names: ADSC therapeutics

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator American CryoStem Corporation; Rutgers
  • Class Cytokines; Extracellular matrix proteins; Growth factors; Stem cell factors; Stem cell therapies; Tissue extracts
  • Mechanism of Action Cell replacements; Cytokine stimulants; Growth stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic wounds; Skin ulcer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Chronic-wounds in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Skin-ulcer in USA (Parenteral)
  • 14 May 2013 American CryoStem and Rutgers, the State University of New Jersey, sign a Material Transfer Agreement to research, develop and commercialise adipose-derived stem cells (ADSCs) in the US for Chronic wounds and Skin ulcers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top